Sei Investments Co. Purchases Shares of 22,802 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Sei Investments Co. acquired a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 22,802 shares of the company’s stock, valued at approximately $49,000.

A number of other large investors have also bought and sold shares of the stock. Intech Investment Management LLC grew its holdings in Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after acquiring an additional 6,340 shares during the last quarter. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics during the 4th quarter valued at approximately $42,000. Raymond James Financial Inc. purchased a new stake in Black Diamond Therapeutics in the 4th quarter worth approximately $53,000. SLT Holdings LLC bought a new stake in shares of Black Diamond Therapeutics in the 4th quarter worth approximately $66,000. Finally, Rhumbline Advisers increased its stake in shares of Black Diamond Therapeutics by 14.9% during the fourth quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock valued at $120,000 after buying an additional 7,290 shares during the period. 95.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BDTX has been the subject of several research reports. HC Wainwright increased their target price on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, March 18th. Stifel Nicolaus dropped their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.60.

Black Diamond Therapeutics Trading Down 2.1 %

Black Diamond Therapeutics stock opened at $1.39 on Friday. The firm has a market cap of $78.76 million, a price-to-earnings ratio of -1.05 and a beta of 2.81. Black Diamond Therapeutics, Inc. has a 12 month low of $1.20 and a 12 month high of $7.66. The stock has a fifty day simple moving average of $1.85 and a two-hundred day simple moving average of $2.44.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. On average, equities research analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Insider Buying and Selling at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares in the company, valued at $5,658,442.29. This trade represents a 67.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.87% of the stock is owned by corporate insiders.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.